Bank of America’s Acceleron Pharma XLRN Stock Holding History

Bank of America’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-90,800	Closed	-$15.6M	–	9014
2021 Q3	$15.6M	Buy	90,800 +66,200	+269%	+$8.66M	﹤0.01%	2400
2021 Q2	$3.09M	Buy	+24,600	New	+$3.1M	﹤0.01%	3952
2020 Q1	–	Sell	-40,300	Closed	-$2.14M	–	7436
2019 Q4	$2.14M	Buy	+40,300	New	+$1.84M	﹤0.01%	3977
2017 Q4	–	Sell	-40,000	Closed	-$1.49M	–	7361
2017 Q3	$1.49M	Buy	40,000 +10,900	+37%	+$378K	﹤0.01%	4228
2017 Q2	$884K	Buy	29,100 +10,000	+52%	+$290K	﹤0.01%	4516
2017 Q1	$506K	Hold	19,100	–	–	﹤0.01%	4881
2016 Q4	$487K	Buy	+19,100	New	+$605K	﹤0.01%	4822

Bank of America's XLRN Position: Q4 2021 in Review

Bank of America sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 133,738 shares — an estimated $23M sold.

Bank of America first reported a position in XLRN in Q1 2014 and held it in 31 quarters. The position peaked at $23M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Bank of America reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Bank of America sold 133,738 Acceleron Pharma shares in Q4 2021, an estimated $23M.
Bank of America first reported a position in Acceleron Pharma in Q1 2014 and held it in 31 quarters.
Bank of America's Acceleron Pharma position peaked at $23M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Bank of America's 13F filing for Q4 2021, filed 8 Feb 2022.